| Name | Title | Contact Details |
|---|
Throughout our 100 plus year history, Hartig Drug has played a key role in progressive retail practices. Did you know that Hartig Drug opened the first self-service drug store in Iowa and was one of the first pharmacies to employ female pharmacists and store managers? The principles upon which A.J. Hartig founded the company, offering the best product selection and providing fanatical service to his customers, are the corner stone of our company culture today. Hartig Drug has expanded its product offerings in retail and pharmacy and has grown via the addition of many stores throughout the years. Our drug stores and pharmacies are located in communities in Northeast Iowa, Northwest Illinois, and Southwest Wisconsin. Hartig Drug operates retail stores, long-term care pharmacies, and Finley Hartig Homecare, a durable medical equipment company. Additionally, we provide pharmacy services to and for several community critical access hospitals and operate MedOne Healthcare, a pharmacy benefit management company that offers customized prescription benefit plans to businesses, prescription discount programs, prescription mail order service and specialty pharmacy services. Hartig Drug remains active in the communities in which we serve. Our employees, live, work and play in the communities in which we operate. This connection to the community is what drives us every day to provide the best possible service and products to our patients and customers. They are our neighbors. At Hartig Drug, we cherish the faith and trust patients and customers have placed in our brand and the way the Hartig name has become synonymous with value, caring associates and a wide selection of quality merchandise.
Biochemics Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.